Literature DB >> 3886399

Effects of BAY l 5240, a fixed combination of low dose nifedipine and acebutolol on hypertension: comparison with standard dose nifedipine.

P Lejeune, W Gunselmann, L Hennies, K Hess, K Rittgerodt, K Winn, G Gfrerer, U Schreiber.   

Abstract

116 patients from 4 clinics participated in a double blind study to assess the efficacy of (BAY l 5240), a nifedipine-acebutolol fixed combination (10 mg + 100 mg), as compared to nifedipine 20 mg in essential hypertension. During the 10 week study, the mean recumbent blood pressure decreased 1 to 3 h after treatment from 175.5/105.2 to 148.3/88.0 mmHg in the BAY l 5240 group and from 174.3/102.9 to 150.3/86.5 mmHg in the nifedipine group. The results also showed a comparable decrease in the mean systolic (SBP) and diastolic (DBP) blood pressures before treatment (24 h after last tablet) and after physical exertion before and after either drug given for 4 weeks. Doubling of the dose for 4 additional weeks produced a moderate and similar additional decrease in blood pressure. The results show the possibility of treating essential hypertension with a low dose of a beta-adrenergic blocking agent in combination with 10 mg nifedipine. Both regimens were well tolerated. One patient in the BAY l 5240 group and 2 in the nifedipine group, all treated by the same investigator, were withdrawn from the study because of headache during the nifedipine pre-period.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3886399     DOI: 10.1007/bf00635702

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  [Antihypertensive effect and inhibition of the sympathetic nervous system by acebutolol].

Authors:  J M Hardin; A Fournier; J M Alexandre; M Lombaert; G Ronco; J F Bezoc; J Quichaud
Journal:  J Urol Nephrol (Paris)       Date:  1976-09

2.  Long-term therapy of arterial hypertension with nifedipine given alone or in combination with a beta-adrenoceptor blocking agent.

Authors:  S E Husted; H K Nielsen; C K Christensen; O Lederballe Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

3.  Controlled trial of nifedipine and bendroflumethiazide in hypertension.

Authors:  L Hallin; L Andrén; L Hansson
Journal:  J Cardiovasc Pharmacol       Date:  1983 Nov-Dec       Impact factor: 3.105

4.  Nifedipine tablets for systemic hypertension: a study using continuous ambulatory intraarterial recording.

Authors:  R S Hornung; B A Gould; R I Jones; T N Sonecha; E B Raftery
Journal:  Am J Cardiol       Date:  1983-05-01       Impact factor: 2.778

5.  Nifedipine in the treatment of difficult hypertensives.

Authors:  S Dean; M J Kendall
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Effectiveness of combined nifedipine and propranolol treatment in hypertension.

Authors:  Y Yagil; I Kobrin; J Stessman; J Ghanem; B Leibel; D Ben-Ishay
Journal:  Hypertension       Date:  1983 Jul-Aug       Impact factor: 10.190

7.  Comparison of efficacy of a single daily dose of 400 mg acebutolol and 100 mg atenolol in the treatment of arterial hypertension.

Authors:  A S Turner; J C Brocklehurst
Journal:  Curr Med Res Opin       Date:  1983       Impact factor: 2.580

8.  Once-daily dosing of acebutolol in hypertension.

Authors:  R I Ogilvie; P Hamet; J H Kreeft; P Larochelle; A Marquez-Julio
Journal:  J Cardiovasc Pharmacol       Date:  1983 Jan-Feb       Impact factor: 3.105

9.  [The effect of beta-receptor antagonists and diuretics and their combination on blood pressure and pressure-rate product during ergometric work in hypertensive patients (author's transl)].

Authors:  I W Franz
Journal:  Z Kardiol       Date:  1982-01

10.  Antihypertensive effects at rest and during exercise of a calcium blocker, nifedipine, alone and in combination with metoprolol.

Authors:  L G Ekelund; C Ekelund; S Rössner
Journal:  Acta Med Scand       Date:  1982
View more
  4 in total

1.  Co-dergocrine mesylate inhibits the increase in plasma catecholamines caused by nifedipine in essential hypertension.

Authors:  R Kirsten; K Nelson; G Weidinger; D Welzel
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 3.  Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

Authors:  J N Lessem; B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 4.  Combination therapy with calcium-entry blockers and beta-adrenoceptor antagonists in hypertension.

Authors:  P Sever
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.